{"name":"Connolly, Stuart, M.D.","slug":"connolly-stuart-m-d","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"amiodarone beta blocker sotalol","genericName":"amiodarone beta blocker sotalol","slug":"amiodarone-beta-blocker-sotalol","indication":"Atrial fibrillation and atrial flutter (maintenance of normal sinus rhythm)","status":"marketed"}]}],"pipeline":[{"name":"amiodarone beta blocker sotalol","genericName":"amiodarone beta blocker sotalol","slug":"amiodarone-beta-blocker-sotalol","phase":"marketed","mechanism":"Sotalol is a non-selective beta-blocker with additional Class III antiarrhythmic activity that slows heart rate and prolongs the cardiac action potential to prevent arrhythmias.","indications":["Atrial fibrillation and atrial flutter (maintenance of normal sinus rhythm)","Ventricular arrhythmias including life-threatening ventricular tachycardia","Hypertension"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE5KaW1xb19MNXNuUVA1ZkgtTGVacmpFWmNhc3E2Tk1YNTdvTXZBTEd1dG85VThYcFc1Q0otemkzaFRMdDgxQlI3ZFB0UWdoWFFWbDhfbVhhanhkTzdpanhQOUZfeWw0UjBxTzl2eEt3ak1nLWJrcHRPOQ?oc=5","date":"2024-04-15","type":"pipeline","source":"American Heart Association Journals","summary":"The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibitors: An ANNEXA-4 Subanalysis - American Heart Association Journals","headline":"The Efficacy and Safety of Andexanet Alfa in Patients With Acute Gastrointestinal Bleeding While Taking Factor Xa Inhibi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMic0FVX3lxTE5tWWl5Rl82c2ZkRXZLUlpZRjlyRmJtUU9TNDBka0JkbC1WSHpwQ2tkcnVZN3RUTkJVcXhSa1J2d1dFdEJKdFRuOGdnZDVrUGtpQ0t0eC1WZXJTWF90ZDRMN1B0bHVRd2Y3Nk02c2E3N2c4OWs?oc=5","date":"2022-01-05","type":"trial","source":"American Heart Association Journals","summary":"Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials With Interaction Testing by Age and Sex - American He","headline":"Direct Oral Anticoagulants Versus Warfarin in Patients With Atrial Fibrillation: Patient-Level Network Meta-Analyses of ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE1OMFZGN2ZQYkJtTEtHekUwUlRVRzR5TVJEWlh4U081S0c5TFRVbGw1SDgzQ09fM1JNRThEcWo3dmdZSlVyLV9oXzdDOVFLMG9FZTZ0UkpVMzBTTmpUVEU4eQ?oc=5","date":"2019-02-07","type":"trial","source":"NEJM","summary":"Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors - NEJM","headline":"Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXkFVX3lxTE4yREJXZkZyVjRpR2pYeFFsTVpDeXlFTk1IMFh1RW1iejMzLWJVc283MENVMUNJd1hnd0lqcHpXNXRud1Y2dEhxdGpyR0lrTi1fZC1BWXFwTGxjUXo3ZGc?oc=5","date":"2018-06-25","type":"trial","source":"NEJM","summary":"Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter - NEJM","headline":"Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxNVG5vakF1WjJIWnJadG1pYUtGSnA5ZjljbzgzU2FoUmU3VGsxLTcwQlZXUGpWRGpKbFF5ZF9vU0ZpYUh2b1pJUDh0REpSTGtabnJ1ZWpHZ2Y0QVBtTzVsMW9YWHMwLW53UWgzRElFQW14VWtfbFNVRWx2Z2VFMklDUC1lMUFuSGVCRDBIYnRDd25iSTlrcW9QV01GODRFek51ckswcHlpWWhNLXRmY1M0ZlJrTC1ZUnZwNExZeA?oc=5","date":"2018-05-07","type":"regulatory","source":"Fierce Pharma","summary":"Portola's Andexxa bleeding antidote wins FDA nod but will see limited release - Fierce Pharma","headline":"Portola's Andexxa bleeding antidote wins FDA nod but will see limited release","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxOSWN3MXdabkVVUWFwVVYzQ2UzRDVlcUF1RHczTEh1NGVtMjdKMmR6dEotZjZOUVd6VS02VWctWThReFUyM3NVRzZ3eVpucllhQzFLX0NiQ0NsQ3JKQUU5dE9hR2hFVkJGVDYtTVFpQXBqYi1yc1RUeUhXSTFXd2RaVUpvdUhmd1BR?oc=5","date":"2018-05-04","type":"regulatory","source":"drugdiscoverytrends.com","summary":"FDA Approves Portola Pharmaceuticals’ Andexxa - drugdiscoverytrends.com","headline":"FDA Approves Portola Pharmaceuticals’ Andexxa","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBNNTZ4dkFIdGhPT0s3WUpxQllvQ0h2Y1c1OUhWb2h3U1BCTzJPZGhFcjA1dFBvVXlNaGxrZEdWcjhqeXNpTW5UV1laQnRsQVRsWTFNYy1vNXhZMmdPZXJZRw?oc=5","date":"2018-04-30","type":"trial","source":"NEJM","summary":"Apixaban in Patients with Atrial Fibrillation - NEJM","headline":"Apixaban in Patients with Atrial Fibrillation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBqS3M4S2VieGdnWHhxa1NmeEFiU3pOXzhNYUNfQndGMnMwN1dBME5IemxQaURRRFM3R0JqckVSR2hELXB3RXM1Ql9uendNWFNScUR2T2VIeVQzUkU1YkdmUQ?oc=5","date":"2015-11-11","type":"pipeline","source":"NEJM","summary":"Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity - NEJM","headline":"Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE00X0xBRGdsNHFZUlJ1Qk4zLU1aR0ltelBOaGhLeW9JeDA1YjZpYTFpRnhsM3NGaWlVZGJsc3dDR1BVV2dnMURnVGI3bmRZYkJQamNQOHlrdVV4QTZ3VDFEag?oc=5","date":"2009-08-30","type":"trial","source":"NEJM","summary":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation - NEJM","headline":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9LNEd0SFpySXhLWnJ5a1d3LTZEOXZvYy01S3UtTG1sSkljMXZpT1U1YlVZV2VYWDBUMXpUR0t4VW1UZ0ZVZW1IbU9BaFkzOThlUXJtcmRZVDh3ekZiMTFr?oc=5","date":"2007-09-06","type":"trial","source":"NEJM","summary":"Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter - NEJM","headline":"Dronedarone for Maintenance of Sinus Rhythm in Atrial Fibrillation or Flutter","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}